Advertisement
BAX or MDT or SYK
Which Stock Would AI Choose? Baxter International (BAX) vs. Medtronic (MDT) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- BAX reported Q1 2026 earnings that beat estimates with $2.7 billion in sales but faces ongoing challenges in its infusion pump and IV solutions segments amid sector pressure.
- MDT trades at a lower valuation multiple compared to peers and recently announced a $650 million acquisition to expand its pain management portfolio.
- SYK delivered mixed Q1 results with revenue growth offset by a cyberattack impact, while pursuing acquisitions and new product launches in orthopedics and surgical tools.
- Recent market activity shows BAX experiencing higher volatility and steeper year-to-date declines relative to MDT and SYK.
- All three companies operate in the medical technology sector, with exposure to procedure volumes, regulatory factors, and supply chain dynamics influencing relative performance in recent weeks.
- Valuation sensitivity and dividend stability provide contrasting profiles, with MDT appearing more attractively priced on earnings multiples amid broader healthcare sector headwinds.
Introduction
This comparison examines BAX, MDT, and SYK, three established players in the medical technology and healthcare supplies industry. These stocks appeal to traders monitoring sector momentum and long-term investors seeking exposure to aging demographics, procedural demand, and innovation in devices for chronic conditions. The analysis highlights recent price behavior, key operational developments, and relative positioning within a market environment shaped by earnings results, acquisitions, and macroeconomic factors affecting healthcare spending. Readers can gain insights into business model differences, risk profiles, and performance contrasts without reliance on forward projections.
BAX Overview and Recent Performance
Baxter International Inc. provides a range of medical products including renal care, medication delivery, and pharmaceuticals. In recent market activity, BAX shares have traded near multi-year lows around $18.78 amid broader healthcare sector weakness. The company reported first-quarter 2026 results that exceeded Wall Street expectations on both revenue and adjusted earnings, driven by international sales growth, though U.S. demand softness in certain segments persisted. Sentiment has been influenced by a Citigroup downgrade to Sell and ongoing monitoring of geopolitical factors such as Middle East conflicts. Over recent weeks, price action reflected volatility following the earnings release, with the stock remaining sensitive to sector-wide pressures on medical supply demand.
MDT Overview and Recent Performance
Medtronic plc develops and manufactures medical devices focused on cardiovascular, diabetes, neuroscience, and surgical technologies. MDT shares closed recently at approximately $73.81, reflecting declines that have brought the stock near its 52-week low. The company announced plans to acquire SPR Therapeutics for about $650 million to bolster its chronic pain treatment offerings. A cyberattack on its IT network in April did not materially disrupt operations or product availability. With fourth-quarter earnings scheduled for early June, recent analyst commentary has included mixed ratings and some price target adjustments. Performance in recent weeks has shown resilience relative to certain peers despite broader medtech sector softness.
SYK Overview and Recent Performance
Stryker Corporation specializes in orthopedic implants, surgical equipment, and neurotechnology products. SYK shares have traded around $305 in recent sessions, with the stock experiencing pressure following first-quarter results that showed modest constant-currency revenue growth alongside a cyberattack impact. The company has pursued portfolio expansion through acquisitions, including Amplitude Vascular Systems for $835 million, and introduced new products such as the Pangea Plating System. Dividend declarations and consistent procedural demand have provided some support. Recent market activity indicates ongoing sensitivity to earnings and operational disruptions within the orthopedic and surgical device space.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing automated trading systems from hundreds of AI trading bots available on the platform. These bots cover thousands of different tickers across varied market conditions, yet only those demonstrating the strongest alignment with prevailing trends, robust statistics, and suitable risk parameters earn placement in the trending section. Available bots feature diverse trading styles, strategies, timeframes, performance metrics, and ticker sets, enabling users to explore options tailored to specific objectives. Ranges of historical win rates, profit factors, and drawdown statistics are displayed for transparency. For further details on currently trending options, visit Trending AI Robots.
Head-to-Head Comparison
The three companies differ in business emphasis: BAX centers on diversified medical supplies and renal care with greater exposure to volume-sensitive consumables, while MDT maintains a broad device portfolio spanning multiple therapeutic areas and SYK concentrates on orthopedics and surgical instrumentation. Growth drivers include procedural recovery for all, yet MDT and SYK benefit from higher-margin innovation pipelines compared with BAX’s supply-chain focus. Recent momentum has favored MDT’s relative stability and acquisition activity over BAX’s steeper declines and SYK’s post-earnings volatility. Risk factors encompass regulatory and cyber considerations across the group, with BAX showing higher beta sensitivity. Valuation metrics position MDT at a lower price-to-earnings multiple than SYK, while sector sentiment remains cautious amid healthcare spending dynamics.
Tickeron AI Verdict
Based on observable factors including trend consistency, acquisition catalysts, and relative valuation positioning in recent market activity, Tickeron’s AI models currently assign a higher probabilistic preference to MDT among the three. This reflects steadier performance metrics and portfolio expansion moves compared with the more pronounced volatility observed in BAX and the earnings-related pressures on SYK. Outcomes remain subject to evolving sector conditions and individual risk tolerances.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BAX’s FA Score shows that 0 FA rating(s) are green whileMDT’s FA Score has 1 green FA rating(s), and SYK’s FA Score reflects 1 green FA rating(s).
- BAX’s FA Score: 0 green, 5 red.
- MDT’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BAX’s TA Score shows that 3 TA indicator(s) are bullish while MDT’s TA Score has 6 bullish TA indicator(s), and SYK’s TA Score reflects 5 bullish TA indicator(s).
- BAX’s TA Score: 3 bullish, 4 bearish.
- MDT’s TA Score: 6 bullish, 4 bearish.
- SYK’s TA Score: 5 bullish, 5 bearish.
Price Growth
BAX (@Pharmaceuticals: Other) experienced а +10.81% price change this week, while MDT (@Medical/Nursing Services) price change was +17.27% , and SYK (@Medical/Nursing Services) price fluctuated +8.09% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.10%. For the same industry, the average monthly price growth was +5.64%, and the average quarterly price growth was -8.37%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.65%. For the same industry, the average monthly price growth was -0.04%, and the average quarterly price growth was -13.16%.
Reported Earning Dates
BAX is expected to report earnings on Jul 23, 2026.
MDT is expected to report earnings on Aug 25, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+4.10% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (+2.65% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| BAX | MDT | SYK | |
| Capitalization | 11.4B | 104B | 128B |
| EBITDA | 750M | 9.81B | 6.44B |
| Gain YTD | 15.449 | -2.349 | -5.081 |
| P/E Ratio | 87.85 | 21.59 | 35.27 |
| Revenue | 11.3B | 36.4B | 25.3B |
| Total Cash | 2.02B | N/A | 2.97B |
| Total Debt | 9.69B | 28.1B | 14.7B |
BAX | MDT | SYK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 21 | 15 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 3 Undervalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 58 | |
SMR RATING 1..100 | 96 | 94 | 57 | |
PRICE GROWTH RATING 1..100 | 45 | 59 | 59 | |
P/E GROWTH RATING 1..100 | 36 | 60 | 81 | |
SEASONALITY SCORE 1..100 | 50 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (3) in the Medical Specialties industry is in the same range as SYK (9) and is significantly better than the same rating for BAX (95). This means that MDT's stock grew similarly to SYK’s and significantly faster than BAX’s over the last 12 months.
SYK's Profit vs Risk Rating (58) in the Medical Specialties industry is somewhat better than the same rating for MDT (100) and is somewhat better than the same rating for BAX (100). This means that SYK's stock grew somewhat faster than MDT’s and somewhat faster than BAX’s over the last 12 months.
SYK's SMR Rating (57) in the Medical Specialties industry is somewhat better than the same rating for MDT (94) and is somewhat better than the same rating for BAX (96). This means that SYK's stock grew somewhat faster than MDT’s and somewhat faster than BAX’s over the last 12 months.
BAX's Price Growth Rating (45) in the Medical Specialties industry is in the same range as SYK (59) and is in the same range as MDT (59). This means that BAX's stock grew similarly to SYK’s and similarly to MDT’s over the last 12 months.
BAX's P/E Growth Rating (36) in the Medical Specialties industry is in the same range as MDT (60) and is somewhat better than the same rating for SYK (81). This means that BAX's stock grew similarly to MDT’s and somewhat faster than SYK’s over the last 12 months.
| BAX | MDT | SYK | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 57% | 2 days ago 50% | 2 days ago 60% |
| Stochastic ODDS (%) | 2 days ago 59% | 2 days ago 54% | 2 days ago 60% |
| Momentum ODDS (%) | N/A | 2 days ago 55% | 2 days ago 59% |
| MACD ODDS (%) | 2 days ago 40% | 2 days ago 41% | 2 days ago 48% |
| TrendWeek ODDS (%) | 2 days ago 58% | 2 days ago 52% | 2 days ago 54% |
| TrendMonth ODDS (%) | 2 days ago 61% | 2 days ago 45% | 2 days ago 46% |
| Advances ODDS (%) | 2 days ago 56% | 2 days ago 51% | 2 days ago 55% |
| Declines ODDS (%) | 12 days ago 65% | 20 days ago 58% | 17 days ago 53% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 45% | 2 days ago 68% |
| Aroon ODDS (%) | 2 days ago 60% | 2 days ago 56% | 5 days ago 51% |
Advertisement
BAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BAX has been loosely correlated with ALGN. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if BAX jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To BAX | 1D Price Change % | ||
|---|---|---|---|---|
| BAX | 100% | +2.27% | ||
| ALGN - BAX | 64% Loosely correlated | +1.55% | ||
| LUNG - BAX | 53% Loosely correlated | +4.40% | ||
| STE - BAX | 51% Loosely correlated | +2.41% | ||
| SYK - BAX | 51% Loosely correlated | +5.25% | ||
| XRAY - BAX | 47% Loosely correlated | +2.18% | ||
More | ||||
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.